Article PDF first page preview

First page of Cholesterolosis Bulbi in an Eye with Retinal Capillary Hemangioma: A Rare Association with Chemical Analysis

Introduction: Cholesterolosis bulbi is an ocular condition characterized by the accumulation of cholesterol crystals in the vitreous cavity. This case describes the development of anterior chamber cholesterolosis bulbi secondary to retinal capillary hemangioma. Case presentation: A 26-year-old female; tested negative for von Hippel-Lindau (VHL) syndrome; presented with yellow shinny crystals filling the anterior chamber of the left eye and similar depositions filling the vitreous cavity along with re-activated hemangioma with new feeder vessels. She was diagnosed previously with bilateral capillary retinal hemangiomas. Anterior chamber and vitreous washout, and endo-laser photocoagulation for the hemangioma were performed. Analysis of the aqueous sample revealed numerous well-demarcated, rectangular, or polygonal lipid-like crystals on light microscopy. Cholesterolosis bulbi secondary to retinal capillary hemangioma was established. Conclusions: Cholesterolosis bulbi secondary to retinal capillary hemangioma is a rare association and would warrant for extensive tumor or associated complications.

Journal Section:
Case Report
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial